title: Development of immunomonitoring of antibody‑dependent cellular cytotoxicity against neuroblastoma cells using whole blood.
abstract: Neuroblastoma, a childhood tumour of neuroectodermal origin, accounts for 15 % of paediatric cancer deaths, which is often metastatic at diagnosis and despite aggressive therapies, it has poor long-term prognosis with high risk of recurrence. Monoclonal antibody (mAb) therapy targeting GD2, a disialoganglioside expressed on neuroblastoma, has shown promise in recent trials with natural killer cell (NK)-mediated antibody-dependent cellular cytotoxicity (ADCC) thought to be central to efficacy, although other immune effectors may be important. To further enhance therapy, immunomonitoring of patients is essential to elucidate the in vivo mechanisms of action and provides surrogate end points of efficacy for future clinical trials. Our aim was to establish a 'real-time' ex vivo wholeblood (WB) immunomonitoring strategy to perform within the logistical constraints such as limited sample volumes, anticoagulant effects, sample stability and shipping time. A fluorescent dye release assay measuring target cell lysis was coupled with flow cytometry to monitor specific effector response. Significant target cell lysis with anti-GD2 antibody (p < 0.05) was abrogated following NK depletion. NK up-regulation of CD107a and CD69 positively correlated with target cell lysis (r > 0.6). The ADCC activity of WB correlated with peripheral blood mononuclear cells (r > 0.95), although WB showed overall greater target cell lysis attributed to the combination of NK-mediated ADCC, CD16+ granulocyte degranulation and complement- dependent cytotoxicity. Response was maintained in heparinised samples stored for 24 h at room temperature, but not 4 °C. Critically, the assay showed good reproducibility (mean % CV < 6.4) and was successfully applied to primary neuroblastoma samples. As such, WB provides a resourceful analysis of multiple mechanisms for efficient end point monitoring to correlate immune modulation with clinical outcome.
authors.forename: Ferdousi
authors.initials: F
authors.lastname: Chowdhury
authors.forename: Holger N
authors.initials: HN
authors.lastname: Lode
authors.forename: Mark S
authors.initials: MS
authors.lastname: Cragg
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Glennie
authors.forename: Juliet C
authors.initials: JC
authors.lastname: Gray
mesh_terms: D000328:Adult; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology*; D005434:Flow Cytometry; D005732:Gangliosides / Q000378:metabolism*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000276:immunology* / Q000378:metabolism; D009447:Neuroblastoma / Q000097:blood / Q000276:immunology* / Q000473:pathology; D014407:Tumor Cells, Cultured
chemical_list: D005732:Gangliosides; C019403:ganglioside, GD2